Frank Rimerman Advisors LLC Acquires 2,252 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Frank Rimerman Advisors LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,086 shares of the biopharmaceutical company’s stock after purchasing an additional 2,252 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Gilead Sciences were worth $2,690,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Manning & Napier Advisors LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $25,328,000. Legal & General Group Plc grew its stake in Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after buying an additional 93,068 shares in the last quarter. GSA Capital Partners LLP bought a new position in Gilead Sciences in the 1st quarter valued at about $462,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after buying an additional 33,162 shares in the last quarter. Finally, Cetera Investment Advisers boosted its position in shares of Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock worth $15,668,000 after acquiring an additional 119,909 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock worth $3,033,340 in the last quarter. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GILD. BMO Capital Markets upped their target price on Gilead Sciences from $85.00 to $94.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, October 9th. Barclays boosted their target price on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Ten research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.85.

Gilead Sciences Trading Up 0.2 %

GILD opened at $89.00 on Friday. The stock has a market cap of $110.80 billion, a PE ratio of 108.54, a price-to-earnings-growth ratio of 3.07 and a beta of 0.18. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $89.74. The company has a fifty day moving average of $82.46 and a 200-day moving average of $73.44.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 3.76 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is 375.61%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.